<?xml version='1.0' encoding='utf-8'?>
<document id="27350147"><sentence text="Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity."><entity charOffset="64-85" id="DDI-PubMed.27350147.s1.e0" text="4β-Hydroxycholesterol" /></sentence><sentence text="The availability of reliable assays for measuring 4β-hydroxycholesterol (4β-HC), a CYP3A metabolite of cholesterol, is an important step in qualifying this endogenous moiety as a biomarker of CYP3A activity"><entity charOffset="50-71" id="DDI-PubMed.27350147.s2.e0" text="4β-hydroxycholesterol" /><entity charOffset="103-114" id="DDI-PubMed.27350147.s2.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.27350147.s2.e0" e2="DDI-PubMed.27350147.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27350147.s2.e0" e2="DDI-PubMed.27350147.s2.e1" /></sentence><sentence text=" Liquid and gas chromatographic methods with mass spectrometric detection have been developed with varying sensitivities, with or without derivatization" /><sentence text=" Care must be taken to chromatographically resolve 4β-HC from the multiple isobaric cholesterol oxidation products present in plasma, including 4α-hydroxycholesterol (4α-HC)"><entity charOffset="84-95" id="DDI-PubMed.27350147.s4.e0" text="cholesterol" /><entity charOffset="144-165" id="DDI-PubMed.27350147.s4.e1" text="4α-hydroxycholesterol" /><entity charOffset="167-172" id="DDI-PubMed.27350147.s4.e2" text="4α-HC" /><pair ddi="false" e1="DDI-PubMed.27350147.s4.e0" e2="DDI-PubMed.27350147.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27350147.s4.e0" e2="DDI-PubMed.27350147.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27350147.s4.e0" e2="DDI-PubMed.27350147.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27350147.s4.e1" e2="DDI-PubMed.27350147.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27350147.s4.e1" e2="DDI-PubMed.27350147.s4.e2" /></sentence><sentence text=" Plasma concentrations of 4β-HC are low in humans (10-60 ng/ml), lower than many other cholesterol metabolites and far less than cholesterol itself"><entity charOffset="87-98" id="DDI-PubMed.27350147.s5.e0" text="cholesterol" /><entity charOffset="129-140" id="DDI-PubMed.27350147.s5.e1" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.27350147.s5.e0" e2="DDI-PubMed.27350147.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27350147.s5.e0" e2="DDI-PubMed.27350147.s5.e1" /></sentence><sentence text=" Stability of 4β-HC has been established for at least 12 months at -20°C in plasma samples obtained with a typical clinical workflow"><entity charOffset="14-19" id="DDI-PubMed.27350147.s6.e0" text="4β-HC" /></sentence><sentence text=" Oxidation of plasma cholesterol during storage produces both 4β-HC and 4α-HC, and 4α-HC may be used as assessment of sample quality"><entity charOffset="21-32" id="DDI-PubMed.27350147.s7.e0" text="cholesterol" /><entity charOffset="62-67" id="DDI-PubMed.27350147.s7.e1" text="4β-HC" /><entity charOffset="72-77" id="DDI-PubMed.27350147.s7.e2" text="4α-HC" /><entity charOffset="83-88" id="DDI-PubMed.27350147.s7.e3" text="4α-HC" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e0" e2="DDI-PubMed.27350147.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e0" e2="DDI-PubMed.27350147.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e0" e2="DDI-PubMed.27350147.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e0" e2="DDI-PubMed.27350147.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e1" e2="DDI-PubMed.27350147.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e1" e2="DDI-PubMed.27350147.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e1" e2="DDI-PubMed.27350147.s7.e3" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e2" e2="DDI-PubMed.27350147.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27350147.s7.e2" e2="DDI-PubMed.27350147.s7.e3" /></sentence><sentence text=" As 4β-HC concentrations over time in untreated individuals have low intra-individual variability, assay precision and reproducibility are the key assay attributes in assessing CYP3A4 induction, and potentially inhibition"><entity charOffset="4-8" id="DDI-PubMed.27350147.s8.e0" text="4β-HC" /></sentence><sentence text=" Assessment of CYP3A4/5 activity with 4β-HC relies on the differences between pre- and post-dose concentrations, in which each subject acts as their own control"><entity charOffset="38-42" id="DDI-PubMed.27350147.s9.e0" text="4β-HC" /></sentence><sentence text=" To reduce analytical variability, samples from a single subject should be analyzed together to facilitate interpretation of study results" /><sentence text=" As an endogenous biomarker, 4β-HC offers the opportunity for less invasive assessment of CYP3A induction potential of new drugs during clinical development"><entity charOffset="29-33" id="DDI-PubMed.27350147.s11.e0" text="4β-HC" /></sentence><sentence text="" /></document>